Activity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel
- 1 June 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (6), 2230-2235
- https://doi.org/10.1128/aac.00049-07
Abstract
Faropenem was tested against 1,188 middle ear fluid pathogens from children in Israel and Costa Rica. Against Streptococcus pneumoniae and Haemophilus influenzae , faropenem was the most active β-lactam, with activity that was similar to or greater than of the other oral antimicrobial classes studied. Faropenem was also active against Moraxella catarrhalis and Streptococcus pyogenes .Keywords
This publication has 23 references indexed in Scilit:
- Antimicrobial susceptibility and genetic characteristics ofHaemophilus influenzaeisolated from patients with respiratory tract infections between 1987 and 2000, including β-lactamase-negative ampicillin-resistant strainsEpidemiology and Infection, 2006
- Molecular Evolution of β-Lactam-Resistant Haemophilus influenzae : 9-Year Surveillance of Penicillin-Binding Protein 3 Mutations in Isolates from JapanAntimicrobial Agents and Chemotherapy, 2006
- Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccineClinical Therapeutics, 2006
- Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000–2003: PROTEKT US years 1–3Journal of Infection, 2005
- In Vitro Activities of Levofloxacin and Comparable Agents against Middle Ear Fluid, Nasopharyngeal, and Oropharyngeal Pathogens Obtained from Costa Rican Children with Recurrent Otitis Media or Failing Other Antibiotic TherapyAntimicrobial Agents and Chemotherapy, 2005
- Susceptibilities to Levofloxacin in Streptococcus pneumoniae , Haemophilus influenzae , and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United StatesAntimicrobial Agents and Chemotherapy, 2003
- Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzaeAntimicrobial Agents and Chemotherapy, 2002
- Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae , Haemophilus influenzae , and Moraxella catarrhalisAntimicrobial Agents and Chemotherapy, 2002
- Association of Amino Acid Substitutions in Penicillin-Binding Protein 3 with β-Lactam Resistance in β-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzaeAntimicrobial Agents and Chemotherapy, 2001
- Otitis MediaClinical Infectious Diseases, 1994